Inactive Instrument

OYSR POIN

Equities

OYST

US69242L1061

Oyster Point Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 10, 2022 at 04:12 pm EST

Oyster Point Pharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 5.59 million compared to USD 17.94 million a year ago. Net loss was USD 36.75 million compared to USD 17.67 million a year ago. Basic loss per share from continuing operations was USD 1.37 compared to USD 0.68 a year ago.
For the nine months, revenue was USD 12.99 million compared to USD 17.94 million a year ago. Net loss was USD 134.58 million compared to USD 58.6 million a year ago. Basic loss per share from continuing operations was USD 5.03 compared to USD 2.25 a year ago.

Latest news about OYSR POIN

Viatris Completes Acquisitions of Oyster Point Pharma, Famy Life Sciences	23-01-03	MT
Oyster Point Pharma, Inc. Announces Board Resignations	23-01-03	CI
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from NASDAQ Composite Index	23-01-03	CI
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from S&P TMI Index	23-01-03	CI
Viatris Inc. completed the acquisition of Oyster Point Pharma, Inc. from a group of shareholders.	23-01-02	CI
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from S&P Global BMI Index	23-01-02	CI
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from NASDAQ Biotechnology Index	22-12-16	CI
Earnings Flash (OYST) OYSTER POINT PHARMA Reports Q3 Revenue $5.6M	22-11-10	MT
Oyster Point Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
North American Morning Briefing : Midterm Outcome -3-	22-11-09	DJ
Piper Sandler Downgrades Oyster Point Pharma to Neutral From Overweight, Adjusts Price Target to $11 From $15	22-11-08	MT
Chardan Downgrades Oyster Point Pharma to Neutral From Buy on Proposed Sale to Viatris, Trims Price Target to $13 From $22	22-11-08	MT
Health Care Up Amid Deal Activity -- Health Care Roundup	22-11-07	DJ
Stocks Advance Ahead of Tuesday's Midterm Elections	22-11-07	MT
Dow Closes More Than 400 Points Higher Ahead of Midterm Elections	22-11-07	MT
Sector Update: Health Care Stocks Closing Near Monday Session Highs	22-11-07	MT
Stocks Mixed Midday Ahead of Tuesday's Midterm Elections	22-11-07	MT
Sector Update: Health Care Stocks Adding to Monday Gains	22-11-07	MT
Viatris Affirms 2022 Outlook After Third-Quarter Earnings Beat, Signs Deal to Buy Oyster Point Pharma	22-11-07	MT
Top Midday Gainers	22-11-07	MT
Sector Update: Health Care	22-11-07	MT
Oyster Point Pharma Climbs Amid $11/Share Takeover Deal With Viatris	22-11-07	MT
Viatris to Buy Oyster Point Pharma, Famy Life Sciences	22-11-07	MT
Oyster Point Pharma, Inc.’s Board intends to launch Stock Repurchase Program.	22-11-07	CI
Viatris Inc. entered into a definitive agreement to acquire Oyster Point Pharma, Inc. from a group of shareholders for approximately $320 million.	22-11-06	CI

Chart OYSR POIN

Duration

Period

More charts

Company Profile

Oyster Point Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The Company's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray's is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

Sector

More about the company